Bacil Pharma has notified BSE Limited of an upcoming Board of Directors meeting, scheduled for Friday, May 22, 2026. The intimation, filed on May 11, 2026, has been submitted in compliance with Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The board meeting has been convened to consider and pass key resolutions. The following items are on the agenda for the meeting:

• Approval of Audited Financial Results for the quarter and year ended March 31, 2026
• Any other business with the permission of the Chairperson

Meeting Details

The key details of the scheduled board meeting are outlined below:

Regulatory Compliance

The intimation has been filed in accordance with Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates listed companies to notify stock exchanges in advance of board meetings where financial results are to be considered. The filing was submitted to the Listing Department of BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai.

Bacil Pharma Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March 2026. The pharmaceutical company filed the certificate with BSE Limited on 14th April 2026, demonstrating its adherence to regulatory requirements.

Regulatory Compliance Certificate

The certificate was issued by Bigshare Services Pvt. Ltd., the company's Registrar and Transfer Agent, on 6th April 2026. The document confirms that Bacil Pharma Limited has fulfilled all necessary obligations under the SEBI depositories regulations for the quarter ended 31st March 2026.

Key Compliance Confirmations

The certificate validates three critical compliance areas:

• Securities Listing Verification: All securities comprised in dematerialized certificates have been properly listed on stock exchanges where the company's earlier issued securities are traded
• Certificate Cancellation: Physical certificates received for dematerialization have been mutilated and cancelled after due verification by the depository participant
• Record Maintenance: The depository's name has been substituted in the register of members as the registered owner within the stipulated 15-day timeline

Documentation Details

The submission was signed by Mrs. Chaitali Kalpataru Shah, Director of Bacil Pharma Limited, with DIN 11167778. The certificate references SEBI circulars dated 25th January 2019 and related regulatory guidelines that mandate quarterly reporting of dematerialization activities.

Company Information

Bacil Pharma Limited operates from its registered office at G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai. The company maintains its compliance obligations through Bigshare Services Pvt. Ltd., which serves as its Registrar and Transfer Agent for all depositories-related activities.